Abstract
Acute mania is frequently a medical emergency requiring hospitalization for behavioral control, rapid resolution of irritability, agitation, de-escalation of mood, and decreasing of risk-taking behavior. Lithium efficacy in the management of acute mania was reported in 1949 and approved by the US Food and Drug Administration (FDA) in 1970. Chlorpromazine, from the class of typical antipsychotics, was approved for treatment of bipolar disorder in 1973. Typical antipsychotics were frequently used alone and as adjunct for the treatment of bipolar mania for the next 2 decades. Divalproex was approved by the FDA for the treatment of acute mania in 1994. Since the approval of olanzapine in 2000, all five atypical antipsychotics, namely risperidone (2003), quetiapine (2004), ziprasidone (2004), and aripiprazole (2004), have been approved by the FDA for the management of acute mania. Clozapine is the only atypical antipsychotic not FDA approved for any phase of bipolar disorder. This article will systematically review some of the major studies published, randomized controlled monotherapy, and adjunct therapy trials involving five atypical antipsychotics and newer anticonvulsants for the treatment of acute bipolar mania.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 504-509 |
| Number of pages | 6 |
| Journal | Current Psychiatry Reports |
| Volume | 8 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2006 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Acute treatment of mania : An update on new medications. / Gajwani, Prashant; Kemp, David E.; Muzina, David J.; Xia, Guohua; Gao, Keming; Calabrese, Joseph R.
In: Current Psychiatry Reports, Vol. 8, No. 6, 12.2006, p. 504-509.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Acute treatment of mania
T2 - An update on new medications
AU - Gajwani, Prashant
AU - Kemp, David E.
AU - Muzina, David J.
AU - Xia, Guohua
AU - Gao, Keming
AU - Calabrese, Joseph R.
PY - 2006/12
Y1 - 2006/12
N2 - Acute mania is frequently a medical emergency requiring hospitalization for behavioral control, rapid resolution of irritability, agitation, de-escalation of mood, and decreasing of risk-taking behavior. Lithium efficacy in the management of acute mania was reported in 1949 and approved by the US Food and Drug Administration (FDA) in 1970. Chlorpromazine, from the class of typical antipsychotics, was approved for treatment of bipolar disorder in 1973. Typical antipsychotics were frequently used alone and as adjunct for the treatment of bipolar mania for the next 2 decades. Divalproex was approved by the FDA for the treatment of acute mania in 1994. Since the approval of olanzapine in 2000, all five atypical antipsychotics, namely risperidone (2003), quetiapine (2004), ziprasidone (2004), and aripiprazole (2004), have been approved by the FDA for the management of acute mania. Clozapine is the only atypical antipsychotic not FDA approved for any phase of bipolar disorder. This article will systematically review some of the major studies published, randomized controlled monotherapy, and adjunct therapy trials involving five atypical antipsychotics and newer anticonvulsants for the treatment of acute bipolar mania.
AB - Acute mania is frequently a medical emergency requiring hospitalization for behavioral control, rapid resolution of irritability, agitation, de-escalation of mood, and decreasing of risk-taking behavior. Lithium efficacy in the management of acute mania was reported in 1949 and approved by the US Food and Drug Administration (FDA) in 1970. Chlorpromazine, from the class of typical antipsychotics, was approved for treatment of bipolar disorder in 1973. Typical antipsychotics were frequently used alone and as adjunct for the treatment of bipolar mania for the next 2 decades. Divalproex was approved by the FDA for the treatment of acute mania in 1994. Since the approval of olanzapine in 2000, all five atypical antipsychotics, namely risperidone (2003), quetiapine (2004), ziprasidone (2004), and aripiprazole (2004), have been approved by the FDA for the management of acute mania. Clozapine is the only atypical antipsychotic not FDA approved for any phase of bipolar disorder. This article will systematically review some of the major studies published, randomized controlled monotherapy, and adjunct therapy trials involving five atypical antipsychotics and newer anticonvulsants for the treatment of acute bipolar mania.
UR - http://www.scopus.com/inward/record.url?scp=33845907401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845907401&partnerID=8YFLogxK
U2 - 10.1007/s11920-006-0058-3
DO - 10.1007/s11920-006-0058-3
M3 - Article
VL - 8
SP - 504
EP - 509
JO - Current Psychiatry Reports
JF - Current Psychiatry Reports
SN - 1523-3812
IS - 6
ER -